Romiplostim effectiveness stratified on duration of immune thrombocytopenia at initiation

Study identification

• EU PAS number:
  EUPAS32183
• Study ID:
  36382
• Official title and acronym:
  Romiplostim effectiveness stratified on duration of immune thrombocytopenia at initiation
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study status:
  Finalised

Research institutions and networks

Institutions

Amgen

United States

NoviSci, Inc. United States

Study timelines

Date when funding contract was signed

Planned:22/01/2019

Actual:22/01/2019

Study start date

Planned:01/11/2019

Actual:17/10/2019

Data analysis start date

Planned:17/10/2019

Actual:17/10/2019

Date of final study report

Planned:12/06/2020

Actual:16/07/2020

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Amgen

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable